search
Back to results

The Effect of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Fibromyalgia

Primary Purpose

Fibromyalgia

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG
Duloxetine 30 MG
Sponsored by
Ilker Fatih Sari
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fibromyalgia focused on measuring Chronic pain, Electric stimulation therapy, Fibromyalgia, Quality of life, Small fiber neuropathy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female patients aged between 18 and 65 years, newly diagnosed according to the American Rheumatology Association 2016 revised FMS diagnostic criteria Patients who come regularly to sessions for posterior tibial nerve stimulation. Exclusion Criteria: History of fracture/musculoskeletal surgery in the last 3 years Inflammatory joint disease, or neurological disease/neurological deficit with examination Receiving medical treatment for polyneuropathy Contraindications to PNS (pacemaker, epilepsy, diminished skin sensation in the area to be applied).

Sites / Locations

  • Giresun University Faculty of Medicine
  • Ondokuz Mayıs University Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PTNS+Duloxetine

Duloxetine

Arm Description

Posterior tibial nerve stimulation (PTNS), twice weekly, 3-4 days apart + Duloxetine 30 mg 1X1 p.o PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes

Duloxetine 30 mg 1X1 p.o

Outcomes

Primary Outcome Measures

Change from baseline in Numeric Rating Scale (NRS) of pain score at week 4 and 12
NRS was used to evaluate the patients' general pain at rest and during activity (during activities of daily living). Patients were asked to rate their pain from 0 to 10, with 0 indicating no pain and 10 indicating the most severe pain
Change from baseline in Short-Form McGill Pain Questionnaire at week 4 and 12
This questionnaire was used to assess the patients' pain. This questionnaire consisted of 15 descriptive words that evaluated the sensory (11) and affective (4) dimensions of pain. Pain intensity was evaluated as follows: 0=none, 1=mild, 2=moderate, and 3=severe. Three pain scores were obtained: sensory, affective, and total (both sensory and affective). The total present pain intensity index was evaluated using a 6-point Likert rating scale. (0 = no pain, 1 = mild, 2 = discomforting, 3 = distressing, 4 = horrible, and 5 = excruciating)

Secondary Outcome Measures

Change from baseline in Fibromyalgia Impact Questionaire at week 4 and 12
This questionnaire consists of 20 questions evaluating physical function, job status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being of patients with fibromyalgia. It was scored between 0 and 100. High scores indicate high disease severity and low functional status.
Change from baseline in The 36-item Short-Form Health Survey at week 4 and 12
This scale is commonly used to evaluate the quality of life. It consists of eight subscales (physical function, physical role limitation, pain, general health, vitality, social function, social role limitation, and mental health) and a total of 36 items. Each subscale was scored between 0 and 100, with 100 points indicating the best health condition and 0 points indicating the worst health condition

Full Information

First Posted
June 24, 2023
Last Updated
June 30, 2023
Sponsor
Ilker Fatih Sari
search

1. Study Identification

Unique Protocol Identification Number
NCT05937711
Brief Title
The Effect of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Fibromyalgia
Official Title
The Effect of Transcutaneous Posterior Tibial Nerve Stimulation on Pain and Quality of Life in Patients With Fibromyalgia: a Single-blind, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
November 2, 2020 (Actual)
Primary Completion Date
May 23, 2022 (Actual)
Study Completion Date
May 23, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ilker Fatih Sari

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aimed to investigate the effectiveness of posterior tibial nerve stimulation (PTNS) in reducing pain, improving quality of life, and decreasing disease severity in patients with fibromyalgia.
Detailed Description
This prospective, single-blind, randomized controlled trial included female patients newly diagnosed with fibromyalgia who had started duloxetine treatment (30 mg/day). Patients who met the inclusion criteria and agreed to participate in the study were randomized (1:1) into two groups. Group 1 (PTNS+duloxetine) underwent six sessions of posterior tibial nerve stimulation, twice weekly, 3-4 days apart, in addition to duloxetine (30 mg/day). Group 2 (duloxetine) received duloxetine only (30 mg/day). Randomization was performed manually, with assignments placed in opaque and sequentially numbered envelopes by off-site researchers who were not involved in patient care or follow-up. Outcome measures were assessed by two investigators who were blinded to each patient's group. The participants and nerve stimulators were not blinded to the group allocation. Patients were briefed to not disclose which group they were in during the assessment process.Patients in the study group received six sessions of posterior tibial nerve stimulation, twice weekly, 3-4 days apart, in addition to duloxetine; the controls received duloxetine only. The patients were evaluated three times (at baseline, 1st month, and 3rd month). Pain was evaluated using a numeric rating scale, the short-form McGill Pain Questionnaire, and quality of life with a 36-item Short-Form Health Survey (SF-36). Patient functional status and disease severity were evaluated using the fibromyalgia impact questionnaire (FIQ).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
Keywords
Chronic pain, Electric stimulation therapy, Fibromyalgia, Quality of life, Small fiber neuropathy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Outcome measures were assessed by investigators who were blinded to each patient's group.
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PTNS+Duloxetine
Arm Type
Experimental
Arm Description
Posterior tibial nerve stimulation (PTNS), twice weekly, 3-4 days apart + Duloxetine 30 mg 1X1 p.o PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes
Arm Title
Duloxetine
Arm Type
Active Comparator
Arm Description
Duloxetine 30 mg 1X1 p.o
Intervention Type
Other
Intervention Name(s)
Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG
Intervention Description
PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes Duloxetine 30 mg p.o 1X1 (daily)
Intervention Type
Drug
Intervention Name(s)
Duloxetine 30 MG
Intervention Description
Duloxetine 30 mg p.o 1X1 (daily)
Primary Outcome Measure Information:
Title
Change from baseline in Numeric Rating Scale (NRS) of pain score at week 4 and 12
Description
NRS was used to evaluate the patients' general pain at rest and during activity (during activities of daily living). Patients were asked to rate their pain from 0 to 10, with 0 indicating no pain and 10 indicating the most severe pain
Time Frame
At baseline, 4th week and 12th week
Title
Change from baseline in Short-Form McGill Pain Questionnaire at week 4 and 12
Description
This questionnaire was used to assess the patients' pain. This questionnaire consisted of 15 descriptive words that evaluated the sensory (11) and affective (4) dimensions of pain. Pain intensity was evaluated as follows: 0=none, 1=mild, 2=moderate, and 3=severe. Three pain scores were obtained: sensory, affective, and total (both sensory and affective). The total present pain intensity index was evaluated using a 6-point Likert rating scale. (0 = no pain, 1 = mild, 2 = discomforting, 3 = distressing, 4 = horrible, and 5 = excruciating)
Time Frame
At baseline, 4th week and 12th week
Secondary Outcome Measure Information:
Title
Change from baseline in Fibromyalgia Impact Questionaire at week 4 and 12
Description
This questionnaire consists of 20 questions evaluating physical function, job status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being of patients with fibromyalgia. It was scored between 0 and 100. High scores indicate high disease severity and low functional status.
Time Frame
At baseline, 4th week and 12th week
Title
Change from baseline in The 36-item Short-Form Health Survey at week 4 and 12
Description
This scale is commonly used to evaluate the quality of life. It consists of eight subscales (physical function, physical role limitation, pain, general health, vitality, social function, social role limitation, and mental health) and a total of 36 items. Each subscale was scored between 0 and 100, with 100 points indicating the best health condition and 0 points indicating the worst health condition
Time Frame
At baseline, 4th week and 12th week

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Since fibromyalgia is more common in women, female patients were included in the study.
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients aged between 18 and 65 years, newly diagnosed according to the American Rheumatology Association 2016 revised FMS diagnostic criteria Patients who come regularly to sessions for posterior tibial nerve stimulation. Exclusion Criteria: History of fracture/musculoskeletal surgery in the last 3 years Inflammatory joint disease, or neurological disease/neurological deficit with examination Receiving medical treatment for polyneuropathy Contraindications to PNS (pacemaker, epilepsy, diminished skin sensation in the area to be applied).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
İlker Fatih Sarı
Organizational Affiliation
Giresun University Faculty of Medicine, The Department of Physical Medicine and Rehabilitation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Giresun University Faculty of Medicine
City
Giresun
ZIP/Postal Code
28200
Country
Turkey
Facility Name
Ondokuz Mayıs University Faculty of Medicine
City
Samsun
ZIP/Postal Code
55139
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33024295
Citation
Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020 Nov;16(11):645-660. doi: 10.1038/s41584-020-00506-w. Epub 2020 Oct 6.
Results Reference
background
PubMed Identifier
30212264
Citation
Cheng CW, Wong CS, Hui GK, Chung EK, Wong SH. Fibromyalgia: is it a neuropathic pain? Pain Manag. 2018 Sep 1;8(5):377-388. doi: 10.2217/pmt-2018-0024. Epub 2018 Sep 13.
Results Reference
background
PubMed Identifier
23474848
Citation
Uceyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, Casanova-Molla J, Reiners K, Sommer C. Small fibre pathology in patients with fibromyalgia syndrome. Brain. 2013 Jun;136(Pt 6):1857-67. doi: 10.1093/brain/awt053. Epub 2013 Mar 9.
Results Reference
background
PubMed Identifier
32804230
Citation
Lin T, Gargya A, Singh H, Sivanesan E, Gulati A. Mechanism of Peripheral Nerve Stimulation in Chronic Pain. Pain Med. 2020 Aug 1;21(Suppl 1):S6-S12. doi: 10.1093/pm/pnaa164.
Results Reference
background
PubMed Identifier
18164488
Citation
Slavin KV. Peripheral nerve stimulation for neuropathic pain. Neurotherapeutics. 2008 Jan;5(1):100-6. doi: 10.1016/j.nurt.2007.11.005.
Results Reference
background
PubMed Identifier
23748113
Citation
Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013 Nov;154(11):2310-2316. doi: 10.1016/j.pain.2013.06.001. Epub 2013 Jun 5.
Results Reference
background
PubMed Identifier
29238215
Citation
Dabby R, Sadeh M, Goldberg I, Finkelshtein V. Electrical stimulation of the posterior tibial nerve reduces neuropathic pain in patients with polyneuropathy. J Pain Res. 2017 Nov 29;10:2717-2723. doi: 10.2147/JPR.S137420. eCollection 2017.
Results Reference
background
PubMed Identifier
18028042
Citation
Thimineur M, De Ridder D. C2 area neurostimulation: a surgical treatment for fibromyalgia. Pain Med. 2007 Nov-Dec;8(8):639-46. doi: 10.1111/j.1526-4637.2007.00365.x.
Results Reference
background

Learn more about this trial

The Effect of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Fibromyalgia

We'll reach out to this number within 24 hrs